Intelligent Bio Solutions (INBS) Partners with Syrma Johari MedTech, Stock Soars 132%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: stocktwits
- Manufacturing Partnership: INBS's collaboration with Syrma Johari MedTech is expected to reduce annual production costs by 40% and increase gross margins by 20 percentage points while quadrupling manufacturing capacity, positioning the company for a U.S. market launch in 2026.
- Successful Private Placement: The company announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock, raising approximately $10 million, thereby strengthening its financial position for future business expansion.
- Strong Stock Surge: INBS stock closed up 132% on December 31, 2025, and surged 337% from the close on December 30, 2025, to January 9, 2026, becoming a favorite among retail traders, indicating robust market interest.
- Nasdaq Compliance Restored: On January 7, 2026, INBS was notified by Nasdaq that it regained compliance to trade, maintaining a closing bid price of $1.00 or higher for 14 consecutive trading days, which bolstered investor confidence.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
